Italy Hereditary Angioedema Drugs Market Report 2023 to 2030

Italy Hereditary Angioedema Drugs Market Analysis

$ 3999

Italy Hereditary Angioedema Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Hereditary Angioedema Drugs is growing as a result of Increasing Awareness and Diagnosis of disease, Advancements in Treatment Options, Technological Advancements and the regulatory authorities have designated numerous HAE therapies as orphan drugs as a result of this classification, pharmaceutical companies are given some incentives including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas. Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these organisations.

ID: IN10ITRD093 CATEGORY: Rare Diseases GEOGRAPHY: Italy AUTHOR: Gaurav Bhongale

Buy Now

Italy Hereditary Angioedema Drugs Market Analysis Summary

Italy Hereditary Angioedema Drugs Market is valued at around $65.28 Mn in 2022 and is projected to reach $76.85 Mn by 2030, exhibiting a CAGR of 2.06% during the forecast period 2023-2030.

An uncommon genetic condition known as hereditary angioedema (HAE) is characterised by recurrent episodes of swelling in different body areas. It is brought on by a lack or malfunction of certain proteins involved in controlling the immune response. HAE can result in sporadic swelling attacks that are potentially fatal and call for specialised care.

The regulatory authorities have designated numerous HAE therapies as orphan drugs because HAE is categorised as a rare condition. Pharmaceutical companies are given some incentives as a result of this classification, including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D.

The increasing prevalence and diagnosis of HAE around the world have been driving the growth of the global market for HAE therapies. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas.

Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these businesses. They are committed to developing cutting-edge therapy strategies for HAE, including C1 esterase inhibitors, kallikrein inhibitors, and other medicines. These businesses have a significant impact on the global advancement of management and treatment choices for people with hereditary angioedema.

Market Dynamics

Market Drivers

A rare disorder with a high mortality risk is HAE. There is an unmet medical need because there haven't been any efficient and targeted treatments for HAE in the past. Different drug classes are available are C1 Esterase Inhibitors which work by replacing or supplementing the deficient or dysfunctional C1 esterase inhibitor protein. (C1-INH) and two types of C1-INH drugs are available that is Plasma-derived C1-INH examples Berinert, Cinryze, Haegarda and Recombinant C1-INH example Ruconest. Bradykinin B2 Receptor Antagonists block the bradykinin receptor, which is responsible for the symptoms of angioedema example Icatibant and Ecallantide. Selective Bradykinin B2 Receptor Antagonist and this newer class of drugs specifically target the bradykinin B2 receptor example Lanadelumab. The C1-esterase inhibitor segment is accounted to have the highest revenue share during the forecast period. kallikrein inhibitors are anticipated to exhibit the fastest CAGR during the projection period. In an effort to enhance patient outcomes and quality of life, this motivates the development of innovative therapies to target HAE symptoms and underlying causes. Healthcare professionals and the general public are now more aware of HAE throughout time. The need for treatments grows as HAE is better understood and diagnosed. Research advances and scientific developments in fields like genetics, immunology, and molecular biology have helped us comprehend the underlying mechanisms of HAE better. This information makes it easier to create customised treatments that target the particular pathways involved in HAE attacks. Since HAE is considered an uncommon condition, many HAE therapies are designated as orphan drugs by regulatory bodies. Pharmaceutical companies are given some incentives as a result of this classification, including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D.

Development in Hereditary Angioedema Drugs Market Analysis

Garadacimab subcutaneous injections given once a month significantly decreased the attack rate when compared to a placebo, according to research on the effectiveness and safety of subcutaneous administration of CSL312 (garadacimab) for the prophylactic treatment of hereditary angioedema by CSL Behring.

The investigational single injection gene therapy BMN 331 from BioMarin Pharmaceutical aims to alter the HAE disease course. According to preclinical research, BMN 331 can restore the low levels of circulating hC1-INH that induce HAE by transducing hepatocytes.

Additional encouraging interim data from a Phase 2 open-label extension (OLE) study of donidalorsen, an experimental antisense drug for the treatment of people with hereditary angioedema, were released by Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today (HAE).

The Phase 3 Clinical trial study for KalVista Pharmaceutical's KVD900, an oral plasma kallikrein inhibitor, is being conducted for the on-demand treatment of angioedema attacks in adolescent and adult patients who have hereditary angioedema type I or II attacks.

Key players

Shire Alexion Pharmaceuticals CSL Behring Octapharma Grifols Baxter International Kedrion Biopharma Aspen Pharmacare BioMarin Pharmaceutical Novo Nordisk

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Italy Hereditary Angioedema Drugs Market

By Type

Type I
Type II

By Treatment

Acute
Prophylactic

By drugs:

C1 Esterase Inhibitors (C1-INH)
Kallikrein Inhibitors
Bradykinin B2 Receptor Antagonists

Route of Administration

Intravenous
Subcutaneous
Oral

By Distribution channel

Hospital Pharmacies
Retail Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.